Met therapeutic effects in lowering hyperglycemia in obese people, those with T2DM, or those with impaired glucose tolerance may be mostly linked to decreased TNF-α and CX3CL1 production (Szukiewicz et al. 2018). This evidence concerns the gene CX3CL1 and Impaired glucose tolerance.